Zalawadiya, Sandip K.; Lindenfeld, JoAnn; Shah, Ashish; Wigger, Mark; Danter, Matthew; Brinkley, D. Marshall; Menachem, Jonathan; Punnoose, Lynn; Balsara, Keki; Brown Sacks, Suzanne; Ooi, Henry; Perri, Roman; Awad, Joseph; Smith, Sarah; Fowler, Rachel; O’Dell, Heather; Darragh, Callie; Ruzevich-Scholl, Shelly; Schlendorf, Kelly published the artcile< Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus>, Application In Synthesis of 58-97-9, the main research area is hepatitis C virus renal impairment heart transplantation sofosbuvir antiviral.
Donor-derived hepatitis C (dd-HCV) infection may increase the risk of renal impairment (RI) among heart transplantation (HT) recipients. Sofosbuvir, an integral component of HCV direct-acting antivirals (DAAs) has also been linked to RI. To date, no study has examined the trends in renal function for HT recipients of dd-HCV infection and assessed safety and efficacy of Sofosbuvir-based DAAs. Between Sept. 2016 and June 2018, 46 HCV-naive patients and one patient with a history of HCV treated pretransplant, underwent HT from HCV-pos. donors (follow-up available through Oct. 10, 2018). Patients were treated with Ledipasvir-Sofosbuvir (genotype 1) or Sofosbuvir-Velpatasvir (genotype 3) for 12 or 24 wk; no dose adjustments were made for renal function. Data on renal function were available for 23 patients who achieved a sustained virol. response at 12 wk after the treatment (SVR12; cohort A) and 18 patients who completed 1 yr of follow-up (cohort B). All patients tolerated DAAs well with 100% completion rate to the assigned therapy and duration and 100% success at achieving SVR12. In this first and largest reported case series to date of HT recipients with dd-HCV infection, we observed that neither the dd-HCV infection nor its treatment with Sofosbuvir-based DAAs increased the risk of RI. Sofosbuvir-based DAAs appear safe, tolerable, and effective for HCV treatment even in presence of severe RI.
ASAIO Journal published new progress about Antiviral agents (direct-acting antiviral). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Application In Synthesis of 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem